Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Therapeutic Nanoparticles from Grapefruit Juice

Published: Monday, June 10, 2013
Last Updated: Monday, June 10, 2013
Bookmark and Share
Grapefruit-derived nanovectors to deliver targeted drugs to treat cancer.

Researchers used nanoparticles derived from grapefruits to deliver targeted drugs to treat cancer in mice. The technique may prove to be a safe and inexpensive way to make customized therapies.

Nanoparticles are emerging as an efficient tool for drug delivery. Microscopic pouches made of synthetic lipids can serve as a carrier, or vector, to protect drug molecules within the body and deliver them to specific cells.

However, these synthetic nanovectors pose obstacles including potential toxicity, environmental hazards and the cost of large-scale production.

Recently, scientists have found that mammalian exosomes-tiny lipid capsules released from cells-can serve as natural nanoparticles. But making therapeutic nanovectors from mammalian cells poses various production and safety challenges.

A research team led by Dr. Huang-Ge Zhang at the University of Louisville hypothesized that exosome-like nanoparticles from inexpensive, edible plants might be used to make nanovectors to bypass these challenges.

The scientists set out to isolate nanoparticles from the juice of grapefruits, grapes and tomatoes. Their work was funded in part by NIH’s National Cancer Institute (NCI) and National Center for Complementary and Alternative Medicine (NCCAM). The study appeared on May 21, 2013 in Nature Communications.

The researchers found that grapefruit juice yielded the most lipid nanoparticles. They then prepared grapefruit-derived nanovectors (GNVs) and tested them in different cell types. GNVs were taken up by a variety of cells at body temperature.

These nanovectors had no significant effect on cell growth or death rates. They proved to be more stable than a synthetic nanovector and were also taken up by cells more readily.

The scientists next tested the GNVs in mice. Three days after fluorescently labeled GNVs were injected into a tail vein or body cavity, they appeared primarily in the liver, lungs, kidneys and spleen.

After intramuscular injections, GNVs were found predominantly in muscle. After intranasal administration, most were seen in the lung and brain.

Although GNVs could be detected 7 days after tail-vein injection, there were no signs of inflammation or other side effects in the mice from any of the treatments.

In addition, no GNVs appeared to pass through the placenta, suggesting they might be safe during pregnancy.

GNVs proved capable of delivering a broad range of therapeutic agents to targeted cells in culture, including chemotherapy drugs, short interfering RNA (siRNA), a DNA expression vector and antibodies.

The researchers next tested GNVs in mouse models of cancer. GNVs carrying a tumor inhibitor reduced tumor growth and prolonged survival when given intranasally to mice with brain tumors.

When injected into mouse models of colon cancer, GNVs with targeting molecules collected in tumor tissue to deliver therapies and slow tumor growth.

“These nanoparticles, which we’ve named grapefruit-derived nanovectors, are derived from an edible plant, and we believe they are less toxic for patients, result in less biohazardous waste for the environment, and are much cheaper to produce at large scale than nanoparticles made from synthetic materials,” Zhang says.

The GNVs are currently being testing for safety in an early clinical trial of colon cancer patients.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
Tuesday, July 21, 2015
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Thursday, July 02, 2015
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Tuesday, June 09, 2015
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
Wednesday, June 03, 2015
Lipid Nanoparticle Therapeutic Treats Ebola in Monkeys
A newly designed agent was effective in treating monkeys infected with a deadly Ebola virus strain.
Wednesday, May 06, 2015
Possible Treatment for Lethal Pediatric Brain Cancer
NIH-funded preclinical study suggests epigenetic drugs may be used to treat leading cause of pediatric brain cancer death.
Tuesday, May 05, 2015
NIH Study Finds Genetic Link for Rare Intestinal Cancer
Researchers recommend screening for people with family history.
Friday, April 17, 2015
Novel Approach Gives Insights Into Tumor Development
Scientists used a powerful new technique to turn off all the genes in mouse lung cancer cells and test how they affect tumor growth and metastasis.
Tuesday, March 24, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
Range of Molecular Alterations in Head and Neck Cancers Uncovered
TCGA tumor genome sequencing analyses offer new insights into the effects of HPV and smoking, and find genomic similarities with other cancers.
Thursday, January 29, 2015
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Wednesday, January 21, 2015
NIH Exceptional Responders to Cancer Therapy Study Launched
Study to investigate the molecular factors of tumors associated with exceptional treatment responses of cancer patients to drug therapies.
Friday, September 26, 2014
NIH Announces the Launch of 3 Integrated Precision Medicine Trials
ALCHEMIST is for patients with certain types of early-stage lung cancer.
Tuesday, August 26, 2014
NIH Launches 3 Integrated Precision Medicine Trials
Findings to answer questions about addition of targeted therapies in earlier stage disease and help understand the prevalence and natural history of these genomic changes in earlier stage lung cancer.
Wednesday, August 20, 2014
GTEx Project to Expand Functional Studies of Genomic Variation
Larger set of human tissues to be analyzed to contribute to a database and tissue bank that researchers can use to study how genomic variants influence gene activity.
Wednesday, August 06, 2014
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!